NIH × Interventional × Carcinoma, Medullary × Clear all
NCT02867592 2026-04-13

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
NCT04514484 2026-03-23

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

Phase 1 Active not recruiting
8 enrolled
NCT00002608 2013-07-10

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
30 enrolled
NCT00019331 2013-06-20

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
NCT00004074 2013-02-28

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled
NCT00005842 2013-02-11

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
NCT00068497 2013-01-14

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase NA Completed
40 enrolled